Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TNXP

Tonix Pharmaceuticals Holding Corp

Mar 12 • 04:00PM ET

13.41

-0.57 -4.08 %

Healthcare • Biotechnology • USA • NASD

Mar 12, 8:15 PMTonix Pharma posts Q4 2025 results with non-GAAP EPS -$3.98 (+59% YoY), revenue $5.4M (+109% YoY), misses EPS, beats revenue and highlights TONMYA fibromyalgia launch

Peers: DMAC KRRO ACIU ELDN INBX INMB VYGR TVGN SOPH BTMD

| Held by: VTI IWM VXF IWN VTWO IWC ITOT AVSC VTWV RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-986.99	Insider Own	0.05%	Shs Outstand	12.79M	Perf Week	-2.26%
Market Cap	171.49M	Forward P/E	-	EPS next Y	-3.09	Insider Trans	0.00%	Shs Float	12.78M	Perf Month	-15.71%
Enterprise Value	-18.15M	PEG	-	EPS next Q	-2.58	Inst Own	29.40%	Short Float	16.46%	Perf Quarter	-31.58%
Income	-99.22M	P/S	16.65	EPS this Y	46.49%	Inst Trans	12.24%	Short Ratio	5.26	Perf Half Y	-50.31%
Sales	10.30M	P/B	0.59	EPS next Y	60.37%	ROA	-57.12%	Short Interest	2.10M	Perf YTD	-14.15%
Book/sh	22.73	P/C	0.90	EPS next 5Y	47.57%	ROE	-64.99%	52W High	69.97 -80.83%	Perf Year	0.00%
Cash/sh	14.86	P/FCF	-	EPS past 3/5Y	52.42% 73.03%	ROIC	-42.88%	52W Low	12.80 4.77%	Perf 3Y	-99.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	15.55%	Volatility	5.36% 5.09%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-1.76	EPS Y/Y TTM	81.36%	Oper. Margin	-969.97%	ATR (14)	0.81	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	9.62	Sales Y/Y TTM	-8.79%	Profit Margin	-963.38%	RSI (14)	35.90	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.89	EPS Q/Q	84.32%	SMA20	-6.29%	Beta	1.82	Target Price	66.33
Payout	-	Debt/Eq	0.00	Sales Q/Q	16.58%	SMA50	-14.58%	Rel Volume	0.60	Prev Close	13.98
Employees	81	LT Debt/Eq	0.00	Earnings	Mar 12 AMC	SMA200	-48.32%	Avg Volume	399.90K	Price	13.41
IPO	Feb 03, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.76% 81.68%	Trades		Volume	255,084	Change	-4.08%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy	$4
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy	$6
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform	$18 → $10
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform	$18
Feb-17-15	Reiterated	ROTH Capital	Buy	$10 → $12
Sep-29-14	Reiterated	ROTH Capital	Buy	$17 → $10

Mar-12-26 05:30PM	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (GlobeNewswire)
Mar-10-26 08:00AM	Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia (GlobeNewswire)
Mar-09-26 04:30PM	Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting (GlobeNewswire)
04:30PM	Tonix Pharmaceuticals Presented Data on TONMYA in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting (GlobeNewswire)
Mar-05-26 04:15PM	Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development (GlobeNewswire)
04:30PM	Loading…
Mar-03-26 04:30PM	Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting (GlobeNewswire)
07:04AM	Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting (Benzinga)
06:00AM	Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market (GlobeNewswire)
Feb-25-26 07:00AM	Tonix Pharmaceuticals to Participate in Two Investor Conferences in March (GlobeNewswire)
Jan-30-26 07:00AM	Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit (GlobeNewswire) -5.38%
Jan-06-26 07:00AM	Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 (GlobeNewswire)
Dec-30-25 08:00AM	Tonix prices 615,025 shares at $16.26 in registered direct offering (TipRanks)
Dec-29-25 07:57AM	Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering (GlobeNewswire)
07:45AM	Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) (GlobeNewswire)
Dec-16-25 07:00AM	Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University (GlobeNewswire)
07:00AM	Loading…
Dec-09-25 07:00AM	Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel (GlobeNewswire)
Nov-24-25 07:00AM	Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder (GlobeNewswire) -11.27%
Nov-17-25 07:00AM	Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment (GlobeNewswire) +5.69%
Nov-10-25 04:15PM	Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire)
Nov-06-25 07:00AM	Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference (GlobeNewswire)
Nov-04-25 07:00AM	Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection (GlobeNewswire) -6.53%
Oct-29-25 11:57AM	Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine Data (Insider Monkey)
Oct-28-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025 (GlobeNewswire)
Oct-27-25 07:00AM	Tonix Pharmaceuticals Presented Data on Tonmya (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence (GlobeNewswire)
Oct-22-25 07:00AM	Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital (GlobeNewswire)
Oct-21-25 07:00AM	Tonix Pharmaceuticals to Present Poster on Tonmya at the 2025 American College of Rheumatology (ACR) Convergence (GlobeNewswire)
Oct-17-25 07:00AM	Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress-Europe 2025 (GlobeNewswire)
Oct-14-25 07:00AM	Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation (GlobeNewswire)
Oct-09-25 07:00AM	Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 (GlobeNewswire)
Sep-30-25 08:30AM	Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access (GlobeNewswire)
03:46AM	Loading…
03:46AM	Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain? (Pharma Voice)
Sep-29-25 07:00AM	Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 (GlobeNewswire)
Sep-18-25 08:00AM	Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder (GlobeNewswire)
Sep-17-25 07:00AM	Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800) (GlobeNewswire)
Sep-08-25 07:00AM	Tonix Pharmaceuticals Presents Clinical Data on Tonmya for the Treatment of Fibromyalgia at PAINWEEK 2025 (GlobeNewswire)
Aug-28-25 07:00AM	Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-18-25 01:07PM	FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide (Investor's Business Daily) -21.97%
09:45AM	Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years (Benzinga)
09:04AM	FDA Approves New Fibromyalgia Drug, Tonix Shares Climb (Investor's Business Daily)
05:02AM	FDA approves Tonixs Tonmya to treat fibromyalgia (Pharmaceutical Technology)
Aug-15-25 03:44PM	Tonix Pharmaceuticals Announces FDA Approval of Tonmya (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia (GlobeNewswire) -13.81%
Aug-11-25 04:15PM	Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire) +32.89%
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire)
Jul-21-25 07:00AM	Tonix Pharmaceuticals Announces the Launch of the "Move Fibro Forward" Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia (GlobeNewswire)
Jul-10-25 07:00AM	Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025 (GlobeNewswire) +10.43%
Jul-09-25 04:01PM	Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine (GlobeNewswire) +7.87%
Jul-07-25 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 (GlobeNewswire)
Jul-02-25 07:00AM	Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models (GlobeNewswire) -5.71%
Jul-01-25 07:23AM	Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes (TipRanks)
Jun-30-25 07:00AM	Tonix Pharmaceuticals Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-16-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025 (GlobeNewswire) +15.60%
Jun-13-25 07:00AM	Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors (GlobeNewswire) -7.41%
Jun-10-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention (GlobeNewswire)
Jun-05-25 07:00AM	Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 (GlobeNewswire)
May-22-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase (GlobeNewswire) -6.81%
May-21-25 07:00AM	Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction (GlobeNewswire) -5.25%
May-14-25 07:00AM	Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations (GlobeNewswire) +9.42%
May-12-25 04:30PM	Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights (GlobeNewswire) +5.16%
Apr-29-25 09:05AM	Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting (GlobeNewswire)
Apr-24-25 07:55AM	Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025 (GlobeNewswire) -6.71%
Apr-10-25 09:24AM	Why Tonix Pharmaceuticals Corp. (TNXP) Went Down On Thursday? (Insider Monkey)
Apr-09-25 07:00AM	Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies (GlobeNewswire) -9.64%
Apr-07-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting (GlobeNewswire) +13.81%
Apr-02-25 07:00AM	Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference (GlobeNewswire)
Apr-01-25 07:00AM	Tonix Pharmaceuticals Launches TONIX ONE , a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition (GlobeNewswire)
Mar-31-25 07:00AM	Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year (ACCESSWIRE) -11.38%
Mar-27-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting (GlobeNewswire) -7.27%
Mar-26-25 02:30AM	Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years (SeekingAlpha)
Mar-25-25 01:00PM	Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (SeekingAlpha)
09:10AM	Pharma Frenzy: Volatility Ignites Biotech Sector (MarketBeat)
Mar-24-25 08:00AM	Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia (GlobeNewswire) +32.48%
Mar-20-25 07:00AM	As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread (ACCESSWIRE) +10.44%
Mar-18-25 04:30PM	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (GlobeNewswire) +26.11% -19.78%
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) +9.97%
Mar-13-25 07:00AM	Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
07:30AM	Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target (ACCESSWIRE)
Mar-11-25 07:00AM	Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th (GlobeNewswire)
Mar-10-25 08:00AM	Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate (GlobeNewswire)
Mar-09-25 06:44PM	Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week (Insider Monkey)
Mar-07-25 01:40PM	Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared on Thursday (Insider Monkey) -11.00%
Mar-06-25 01:34PM	A 41% Surge? This Small-Cap Pharma Stock Just Shook Up the Fibromyalgia Market (GuruFocus.com) +33.49%
01:23PM	Tonix Surges 31% Following Positive Phase 3 Fibromyalgia Drug Trial Results (GuruFocus.com)
Mar-05-25 07:00AM	Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit (GlobeNewswire) +40.51%
Mar-04-25 07:00AM	Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia (GlobeNewswire) +5.69%
Feb-07-25 11:43AM	Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500 (Clinical Trials Arena) +10.23%
08:30AM	Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash (GlobeNewswire)
Feb-06-25 08:00AM	Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases (GlobeNewswire) -24.97%
Feb-05-25 07:00AM	Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference (GlobeNewswire)
Feb-04-25 07:00AM	Tonix Pharmaceuticals Promotes Siobhan Fogarty to Chief Technical Officer (GlobeNewswire) -21.96%
Feb-03-25 08:05AM	Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock Split (GlobeNewswire) -54.47%
Jan-08-25 07:00AM	Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access (GlobeNewswire) -11.14%
Jan-07-25 07:00AM	Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences (GlobeNewswire) -7.81%
Dec-23-24 08:00AM	Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia (GlobeNewswire) -34.09%
Dec-17-24 08:00AM	Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia (GlobeNewswire) -37.00%
Dec-16-24 11:40AM	Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +120.37%
Dec-09-24 07:30AM	Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers (ACCESSWIRE)
Dec-03-24 07:00AM	Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires (GlobeNewswire)
Nov-26-24 07:00AM	Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference (GlobeNewswire)

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Taylor Carolyn E.	Director	Aug 21 '25	Buy	36.03	418	15,061	418	Aug 21 05:22 PM
Treco James	Director	Aug 20 '25	Buy	36.00	250	9,000	250	Aug 20 04:15 PM
LEDERMAN SETH	Chief Executive Officer	May 15 '25	Buy	21.55	4,000	86,200	4,005	May 15 05:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNXP

Tonix Pharmaceuticals Holding Corp

Upgrade your FINVIZ experience